Cargando…

Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)

Cobalamin deficiency is relatively common, but the great majority of cases in epidemiologic surveys have subclinical cobalamin deficiency (SCCD), not classical clinical deficiency. Because SCCD has no known clinical expression, its diagnosis depends solely on biochemical biomarkers, whose optimal ap...

Descripción completa

Detalles Bibliográficos
Autor principal: Carmel, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Nutrition 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174853/
https://www.ncbi.nlm.nih.gov/pubmed/21593511
http://dx.doi.org/10.3945/ajcn.111.013441
_version_ 1782212083820003328
author Carmel, Ralph
author_facet Carmel, Ralph
author_sort Carmel, Ralph
collection PubMed
description Cobalamin deficiency is relatively common, but the great majority of cases in epidemiologic surveys have subclinical cobalamin deficiency (SCCD), not classical clinical deficiency. Because SCCD has no known clinical expression, its diagnosis depends solely on biochemical biomarkers, whose optimal application becomes crucial yet remains unsettled. This review critically examines the current diagnostic concepts, tools, and interpretations. Their exploration begins with understanding that SCCD differs from clinical deficiency not just in degree of deficiency but in fundamental pathophysiology, causes, likelihood and rate of progression, and known health risks (the causation of which by SCCD awaits proof by randomized clinical trials). Conclusions from SCCD data, therefore, often may not apply to clinical deficiency and vice versa. Although many investigators view cobalamin testing as unreliable, cobalamin, like all diagnostic biomarkers, performs satisfactorily in clinical deficiency but less well in SCCD. The lack of a diagnostic gold standard limits the ability to weigh the performance characteristics of metabolic biomarkers such as methylmalonic acid (MMA) and holotranscobalamin II, whose specificities remain incompletely defined outside their relations to each other. Variable cutoff selections affect diagnostic conclusions heavily and need to be much better rationalized. The maximization of reliability and specificity of diagnosis is far more important today than the identification of ever-earlier stages of SCCD. The limitations of all current biomarkers make the combination of ≥2 test result abnormalities, such as cobalamin and MMA, the most reliable approach to diagnosing deficiency in the research setting; reliance on one test alone courts frequent misdiagnosis. Much work remains to be done.
format Online
Article
Text
id pubmed-3174853
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher American Society for Nutrition
record_format MEDLINE/PubMed
spelling pubmed-31748532012-07-01 Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4) Carmel, Ralph Am J Clin Nutr NHANES Monitoring of Biomarkers of Folate and Vitamin B-12 Status: a Roundtable Review Cobalamin deficiency is relatively common, but the great majority of cases in epidemiologic surveys have subclinical cobalamin deficiency (SCCD), not classical clinical deficiency. Because SCCD has no known clinical expression, its diagnosis depends solely on biochemical biomarkers, whose optimal application becomes crucial yet remains unsettled. This review critically examines the current diagnostic concepts, tools, and interpretations. Their exploration begins with understanding that SCCD differs from clinical deficiency not just in degree of deficiency but in fundamental pathophysiology, causes, likelihood and rate of progression, and known health risks (the causation of which by SCCD awaits proof by randomized clinical trials). Conclusions from SCCD data, therefore, often may not apply to clinical deficiency and vice versa. Although many investigators view cobalamin testing as unreliable, cobalamin, like all diagnostic biomarkers, performs satisfactorily in clinical deficiency but less well in SCCD. The lack of a diagnostic gold standard limits the ability to weigh the performance characteristics of metabolic biomarkers such as methylmalonic acid (MMA) and holotranscobalamin II, whose specificities remain incompletely defined outside their relations to each other. Variable cutoff selections affect diagnostic conclusions heavily and need to be much better rationalized. The maximization of reliability and specificity of diagnosis is far more important today than the identification of ever-earlier stages of SCCD. The limitations of all current biomarkers make the combination of ≥2 test result abnormalities, such as cobalamin and MMA, the most reliable approach to diagnosing deficiency in the research setting; reliance on one test alone courts frequent misdiagnosis. Much work remains to be done. American Society for Nutrition 2011-07 2011-05-18 /pmc/articles/PMC3174853/ /pubmed/21593511 http://dx.doi.org/10.3945/ajcn.111.013441 Text en © 2011 American Society for Nutrition This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) which permit unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle NHANES Monitoring of Biomarkers of Folate and Vitamin B-12 Status: a Roundtable Review
Carmel, Ralph
Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title_full Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title_fullStr Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title_full_unstemmed Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title_short Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II(1)(2)(3)(4)
title_sort biomarkers of cobalamin (vitamin b-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin ii(1)(2)(3)(4)
topic NHANES Monitoring of Biomarkers of Folate and Vitamin B-12 Status: a Roundtable Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174853/
https://www.ncbi.nlm.nih.gov/pubmed/21593511
http://dx.doi.org/10.3945/ajcn.111.013441
work_keys_str_mv AT carmelralph biomarkersofcobalaminvitaminb12statusintheepidemiologicsettingacriticaloverviewofcontextapplicationsandperformancecharacteristicsofcobalaminmethylmalonicacidandholotranscobalaminii1234